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Abstract
As societies around the world are ageing, the number of Alzheimer’s disease (AD)
patients is rapidly increasing. To date, no low-cost, non-invasive biomarkers have
been established to advance the objectivization of AD diagnosis and progression
assessment. Here, we utilize Bayesian neural networks to develop a multivari-
ate predictor for AD severity using a wide range of quantitative EEG (QEEG)
markers. The Bayesian treatment of neural networks both automatically controls
model complexity and provides a predictive distribution over the target function,
giving uncertainty bounds for our regression task. It is therefore well suited to
clinical neuroscience, where data sets are typically sparse and practitioners re-
quire a precise assessment of the predictive uncertainty. We use data of one of
the largest prospective AD EEG trials ever conducted to demonstrate the potential
of Bayesian deep learning in this domain, while comparing two distinct Bayesian
neural network approaches, i.e., Monte Carlo dropout and Hamiltonian Monte
Carlo.
1 Introduction
Alzheimer’s disease (AD) is the most common form of dementia and highly prevalent among elderly
individuals. As societies around the world are ageing, the number of patients affected is rapidly in-
creasing. AD is associated with an enormous disease burden regarding morbidity, mortality, and
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financial expenses. It impairs basic bodily functions such as walking and swallowing, has devastat-
ing impact on memory and cognition, and is ultimately fatal. The costs of care for individuals with
AD or other dementias are already enormous [1], dementia being one of the costliest conditions to
society [2].
Since AD progresses over time, early accurate diagnosis and precise clinical monitoring would
be essential. Yet, in daily clinical routine, AD assessment is usually done by subjective clinical
interpretations once there is a strong prior that the disease is already at a progressed stage.
To date, no low-cost, non-invasive biomarkers have been established to advance the objectivization
of diagnosis and disease progression assessment. For a wide use, such markers should not rely on
expensive equipment (e.g., scanners for magnetic resonance imaging (MRI), or positron emission
tomography (PET)), or require invasive procedures (injection of a positron emitter (PET), or lumbar
puncture (analysis of cerebrospinal fluid)). Properties like non-invasiveness, cost-effectiveness and
a wide availability make electroencephalography (EEG) a potential candidate modality for such
markers. Various studies have shown associations between quantitative EEG (QEEG) markers of
slowing, complexity, and functional connectivity and AD (for reviews, see [3, 4]).
Here, we utilize Bayesian neural networks [5] to develop a multivariate predictor for AD severity,
as measured by the Mini-Mental State Examination (MMSE). We use 820 distinct QEEG markers
as features, all belonging to the aforementioned categories of slowing, complexity, and functional
connectivity.
Bayesian techniques allow for an adjustment of predictions through varying priors. Therefore poten-
tial variations in diagnostic settings (distinct locations) or distinct disease prevalence (varying age
groups) can be accounted for. Furthermore, Bayesian approaches provide probabilistic predictions
quantifying predictive uncertainty – which is of utmost importance for medical practitioners. Finally,
the Bayesian treatment of neural networks prevents over-fitting to sparse data sets as typically found
in clinical neuroscience.
To demonstrate the potential of Bayesian deep learning techniques, we investigate the performance
of two different Bayesian approaches, i.e., (1)Monte Carlo dropout [6] (MC dropout BNN) and (2)
Hamiltonian Monte Carlo [7] (HMC BNN), and compare their results to traditional (non-Bayesian)
networks (NN). All models use identical QEEG features from one of the largest prospective AD
EEG trials ever conducted.
2 Materials and Methods
2.1 Experimental data
One hundred and eighty-eight AD patients (133 with probable, 55 with possible AD diagnosis ac-
cording to NINCDS-ADRDA criteria; 100 females; mean age 74.86±8.06 standard deviation (SD);
mean MMSE score 22.84 ±3.70 SD; mean years of education 11.14 ±3.04 SD; mean duration of
illness (months) 26.88 ±24.11 SD ; 115 (61.17%) with anti-dementia medication) were considered
for this investigation. They were recruited prospectively at the tertiary-referral memory clinics of
the neurological departments at the Medical Universities of Graz, Innsbruck and Vienna, as well
as Linz General Hospital as part of the PRODEM (Prospective Dementia Database Austria) cohort
study. Assessment of disease severity was done using the MMSE [8]. Continuous EEG (alpha trace
EEG recorder, 10-20 electrode placement) was analyzed for an eyes-closed (180 sec) and an eyes-
open resting condition (180 sec). For details on the entire PRODEM experimental protocol and
preprocessing pipeline, see [9–11].
2.2 Feature generation
In total, 820 QEEG markers were computed considering various measures of slowing (absolute
band power, relative band power, center frequency), complexity (auto-mutual information, Shannon
entropy, Tsallis entropy), and functional connectivity (coherence, partial coherence, phase coher-
ence, canonical correlation, dynamic canonical correlation, Granger causality, conditional Granger
causality, cross-mutual information), as well as two resting state conditions (eyes-closed, eyes-open),
various brain regions [12, 3], and multiple frequency bands [12].
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Features were normalized and projected into a lower-dimensional space (five components) using
principal components analysis, before passing the data to the models.
2.3 Bayesian neural networks
In this paper we use Bayesian neural networks (BNNs) as our model for regression [13, 5]. These
are neural networks, where we define the prior p(ωl) for each layer l ∈ L as a product of multi-
variate normal distributions
∏
L
l=1
N (0, I/λl) (where λl is the prior length-scale) and the Gaussian
likelihood p(y | ω,x) as N (fω(x), σ2), where σ2 is the noise variance. Assigning probability
distributions over the weights leads to a function approximation fω(x) that is also a distribution.
Therefore, we are also provided with important uncertainty estimates of our predictions.
In the presence of data {X,Y}, we can perform inference to get the posterior distribution over the
weights,
p(ω | X,Y) =
p(Y | ω,X)p(ω)
p(Y | X)
, (1)
which requires the normalizing distribution, otherwise known as the marginal likelihood,
p(Y | X) =
∫
ω
p(Y | ω,X)p(ω)dω. (2)
The inferred posterior distribution is then used to form the predictive distribution over a new test
point x∗,
p(y∗ | x∗) =
∫
ω
p(y∗ | ω,x∗)p(ω | X,Y)dω. (3)
The integrations in Equations (2) and (3) are analytically intractable, which is the bottleneck in
BNNs. To perform these integrations there are two common solutions. One solution is to replace
the true posterior with a variational approximation that is either cheaper to sample from [14] or
conjugate to the likelihood [13]. The other option is to use a Markov Chain Monte Carlo technique
such as Hamiltonian Monte Carlo [7] to sample from the posterior.
In this work, we make a direct comparison between two BNN implementations:
1. MC dropout [6], which is a variational approximation.
2. HamiltonianMonte Carlo [7], which is a Markov Chain Monte Carlo technique that utilises
Hamiltonian dynamics to explore the parameter space of networks.
In addition, we also implement a standard (non-Bayesian) neural network as a useful baseline.
MC dropout is a variational approximation which implements dropout at test time of a neural net-
work, as well as during training. A dropout mask is drawn from Bernoulli distributed random vari-
ables and sets a proportion of the weights in the network to zero. Dropping these weights at test
time gives an approximation to the predictive distribution by sampling T new dropout masks for
each forward-pass through the network. This results in T samples that represent the predictive dis-
tribution.
Hamiltonian Monte Carlo can be used to infer the predictive distribution in Equation (3) by intro-
ducing a Hamiltonian,
H(ω,p) = E(ω) +K(p), (4)
that defines the total energy. This introduces an additional momentum variable p, which is used to
form the kinetic energyK(p). However, our interest lies in the potential energy E(ω) as
E(ω) ∝ − log(p(ω | X,Y)). (5)
Given this Hamiltonian, we define a distribution over the phase space p(ω,p) ∝ exp(−H(ω,p)).
Therefore in sampling from this distribution and ignoring the momentumparameters, we can retrieve
the posterior distribution overω, by using the Hamiltonian dynamics to sample from the phase space.
For further details, we refer to Neal [5].
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2.4 Metrics for comparison
To compare results across the model we use both the mean squared error (MSE) and the standardized
mean squared error (SMSE) [15], where forN test points, we define
SMSE =
1
N
N∑
i=1
(yi − f˜ω(xi))2
σ
2
i
. (6)
The SMSE is the MSE normalised by the predictive variance σ2
i
and we also define the predictive
mean for a given data point xi as f˜
ω(xi). This is an appropriate metric for regression tasks, where
we are also interested in the model predictive variance.
2.5 Nested cross-validation and grid search
A two-level nested cross-validation (5 × 5) was used to determine generalization performance. We
included a nested loop to perform a grid search to select the hyperparameter settings with minimal
expected generalization error. For the HMC BNN, we optimized for the prior weight precision (see
[5] for an intuition behind the weight precision) and for the MC dropout network, we optimized for
dropout, which is directly related to the weight precision (see [14] for details of the relationship).
We also used the nested loop to optimize for the dropout rate and early stopping for the standard
NN. In addition to selecting these hyperparameters in our grid search, we also searched through a
range of small neural network architectures, with the smallest having a hidden layer of 100 units to
the largest having two hidden layers of 300 units.
3 Results and Discussion
For each of the five outer-fold test sets, we first selected the optimal hyperparameters for each type
of network (HMCBNN, MC dropout BNN and NN) based on the performance in the five inner folds
of the nested cross-validation loop. Then, we used the corresponding settings to compute the results
in the outer folds, as reported in Table 1.
Overall, HMC BNNs significantly (p < 0.05) outperformed MC dropout BNNs and standard NNs.
Differences between model performances were assessed by statistically comparing squared errors
of test set predictions.
All Bayesian models selected for the outer folds had two hidden layers of 100 units. The BNNs
showed an average lower MSE than the best standard NN across the test sets. This highlights the
importance of combining the function approximating power of neural networks with Bayesian tech-
niques. This is especially true for sparse data sets. In the present study, the data set consisted of 188
patients, which allowed us to directly compute the derivatives in the Hamiltonian. As such, we saw
the HMC BNN outperforming the MC dropout BNN, which is often seen in practice [16]. The com-
parably high SMSE values for the MC dropout model is due to the underestimation of the predictive
uncertainty. This is a common limitation of variational inference techniques as the approximate pos-
terior is optimised through an objective that is mode-seeking and can fail in modelling probability
mass far away from the mode. In larger data sets, approximate inference (such as MC dropout) is
currently the most practical way to implement BNNs.
Overall, we have shown how BNNs can be used to facilitate the development of low-cost, non-
invasive markers of AD severity. To the best of our knowledge, this is the first article reporting a
BNN approach for building QEEG markers of AD severity.
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Table 1: Mean squared error (MSE) and the standardized mean squared error (SMSE) of outer loop
test sets (nested cross-validation) for predicting AD severity, as measured by the Mini-Mental State
Examination (MMSE) for the HMC Bayesian neural networks (HMC BNN), MC dropout Bayesian
neural networks (MC dropout BNN) and standard neural networks (NN).
HMC BNN MC dropout BNN NN
Test set MSE SMSE MSE SMSE MSE SMSE
1 12.42 15.21 17.29 1198.36 23.56 n.a.
2 14.95 185.41 13.94 1027.51 24.94 n.a.
3 11.49 144.14 13.40 1030.63 20.39 n.a.
4 14.36 173.73 19.81 708.82 81.21 n.a.
5 7.65 101.62 18.91 775.49 18.45 n.a.
1-5 12.17 124.02 16.67 948.16 33.71 n.a.
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